Form 4: Puma Biotech CFO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, sold a total of 10,945 shares of common stock in early January 2026 under a pre-arranged 10b5-1 trading plan.
Summary
- Maximo F. Nougues, Chief Financial Officer of Puma Biotechnology, Inc. (PBYI), reported sales of common stock.
- The transactions were executed pursuant to a Rule 10b5-1(c) plan, which was adopted on December 14, 2020.
- On January 6, 2026, 4,540 shares of common stock were disposed of at a price of $5.844 per share.
- On January 7, 2026, an additional 6,405 shares of common stock were disposed of at a price of $5.879 per share.
- Following these transactions, Maximo F. Nougues beneficially owns 193,284 shares of Puma Biotechnology, Inc. common stock directly.
Sentiment
Score: 5
Explanation: The filing reports routine insider sales by the CFO under a pre-arranged 10b5-1 plan. While insider selling can sometimes be viewed cautiously, the pre-scheduled nature of these transactions for personal financial planning typically makes them less impactful than unscheduled sales, resulting in a neutral sentiment.
Negatives
- Insider selling, even under a pre-arranged 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence or a desire for diversification, potentially leading to negative sentiment.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may interpret the insider selling with caution, though the pre-arranged 10b5-1 plan mitigates concerns about sales based on new, non-public information.
Key Dates
| Date | Description |
|---|---|
| 12-14-2020 | Adoption date of the referenced 10b5-1(c) plan. |
| 01/06/2026 | Date of first reported transaction (disposal of 4,540 shares). |
| 01/07/2026 | Date of second reported transaction (disposal of 6,405 shares). |
| 01/08/2026 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThe filing reports routine insider sales by the CFO under a pre-arranged 10b5-1 plan. These transactions are typically for personal financial planning and diversification and do not necessarily reflect a change in management's outlook on the company's future performance. The total value of shares sold is relatively small, and therefore, it does not provide sufficient new information to alter an existing investment thesis or warrant a strong buy/sell recommendation.
Keywords
Puma Biotechnology, PBYI, Insider Trading, Form 4, Stock Sale, CFO, Maximo F. Nougues, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.